APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mitogen Activated Protein Kinase 14

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Mitogen Activated Protein Kinase 14 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025195 pages

Choose your research edition.

Industry ResearchMitogen Activated Protein Kinase 14 Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Mitogen Activated Protein Kinase 14 Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Mitogen Activated Protein Kinase 14 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mitogen Activated Protein Kinase 14 Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Mitogen Activated Protein Kinase 14 Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Mitogen Activated Protein Kinase 14 market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Mitogen Activated Protein Kinase 14 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mitogen Activated Protein Kinase 14 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mitogen Activated Protein Kinase 14 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Mitogen Activated Protein Kinase 14 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Mitogen Activated Protein Kinase 14 include Eli Lilly and Company, GlaxoSmithKline Plc, AstraZeneca Plc, Zocere, Inc., Toray Industries, Synovo GmbH, Chroma Therapeutics Limited, Chiesi Farmaceutici SpA and Astellas Pharma Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Mitogen Activated Protein Kinase 14 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mitogen Activated Protein Kinase 14 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mitogen Activated Protein Kinase 14 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mitogen Activated Protein Kinase 14 market size, projected growth trends, production technologies, key applications, and end-use industries.

Mitogen Activated Protein Kinase 14 Segment by Company

Eli Lilly and Company

GlaxoSmithKline Plc

AstraZeneca Plc

Zocere, Inc.

Toray Industries

Synovo GmbH

Chroma Therapeutics Limited

Chiesi Farmaceutici SpA

Astellas Pharma Inc.

Array BioPharma Inc.

Mitogen Activated Protein Kinase 14 Segment by Type

Ralimetinib Mesylate

Neflamapimod

Losmapimod

CHF-6297

Others

Mitogen Activated Protein Kinase 14 Segment by Application

Gastric Cancer

Epithelial Ovarian Cancer

Chronic Inflammation

Ulcerative Colitis

Others

Mitogen Activated Protein Kinase 14 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mitogen Activated Protein Kinase 14 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mitogen Activated Protein Kinase 14 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mitogen Activated Protein Kinase 14.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Mitogen Activated Protein Kinase 14 market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Mitogen Activated Protein Kinase 14 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Mitogen Activated Protein Kinase 14 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Mitogen Activated Protein Kinase 14 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Mitogen Activated Protein Kinase 14 Industry Trends Table 2. Mitogen Activated Protein Kinase 14 Industry Drivers Table 3. Mitogen Activated Protein Kinase 14 Industry Opportunities and Challenges Table 4. Mitogen Activated Protein Kinase 14 Industry Restraints Table 5. Global Mitogen Activated Protein Kinase 14 Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Mitogen Activated Protein Kinase 14 Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Mitogen Activated Protein Kinase 14 Sales Market Share by Manufacturers Table 9. Global Mitogen Activated Protein Kinase 14 Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Mitogen Activated Protein Kinase 14 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Mitogen Activated Protein Kinase 14 Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Mitogen Activated Protein Kinase 14 Manufacturers, Product Type & Application Table 13. Global Mitogen Activated Protein Kinase 14 Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Mitogen Activated Protein Kinase 14 by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ralimetinib Mesylate Table 17. Major Manufacturers of Neflamapimod Table 18. Major Manufacturers of Losmapimod Table 19. Major Manufacturers of CHF-6297 Table 20. Major Manufacturers of Others Table 21. Global Mitogen Activated Protein Kinase 14 Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Mitogen Activated Protein Kinase 14 Sales by Type (2021-2026) & (K Units) Table 23. Global Mitogen Activated Protein Kinase 14 Sales by Type (2027-2032) & (K Units) Table 24. Global Mitogen Activated Protein Kinase 14 Sales Market Share by Type (2021-2026) Table 25. Global Mitogen Activated Protein Kinase 14 Sales Market Share by Type (2027-2032) Table 26. Global Mitogen Activated Protein Kinase 14 Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Mitogen Activated Protein Kinase 14 Revenue by Type (2021-2026) & (K Units) Table 28. Global Mitogen Activated Protein Kinase 14 Revenue by Type (2027-2032) & (K Units) Table 29. Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Type (2021-2026) Table 30. Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Gastric Cancer Table 32. Major Manufacturers of Epithelial Ovarian Cancer Table 33. Major Manufacturers of Chronic Inflammation Table 34. Major Manufacturers of Ulcerative Colitis Table 35. Major Manufacturers of Others Table 36. Global Mitogen Activated Protein Kinase 14 Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Mitogen Activated Protein Kinase 14 Sales by Application (2021-2026) & (K Units) Table 38. Global Mitogen Activated Protein Kinase 14 Sales by Application (2027-2032) & (K Units) Table 39. Global Mitogen Activated Protein Kinase 14 Sales Market Share by Application (2021-2026) Table 40. Global Mitogen Activated Protein Kinase 14 Sales Market Share by Application (2027-2032) Table 41. Global Mitogen Activated Protein Kinase 14 Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Mitogen Activated Protein Kinase 14 Revenue by Application (2021-2026) & (K Units) Table 43. Global Mitogen Activated Protein Kinase 14 Revenue by Application (2027-2032) & (K Units) Table 44. Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Application (2021-2026) Table 45. Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Application (2027-2032) Table 46. Global Mitogen Activated Protein Kinase 14 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Mitogen Activated Protein Kinase 14 Sales by Region (2021-2026) & (K Units) Table 48. Global Mitogen Activated Protein Kinase 14 Sales Market Share by Region (2021-2026) Table 49. Global Mitogen Activated Protein Kinase 14 Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Mitogen Activated Protein Kinase 14 Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Mitogen Activated Protein Kinase 14 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Mitogen Activated Protein Kinase 14 Sales by Country (2021-2026) & (K Units) Table 53. North America Mitogen Activated Protein Kinase 14 Sales by Country (2027-2032) & (K Units) Table 54. Europe Mitogen Activated Protein Kinase 14 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Mitogen Activated Protein Kinase 14 Sales by Country (2021-2026) & (K Units) Table 56. Europe Mitogen Activated Protein Kinase 14 Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Mitogen Activated Protein Kinase 14 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Mitogen Activated Protein Kinase 14 Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Mitogen Activated Protein Kinase 14 Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Mitogen Activated Protein Kinase 14 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Mitogen Activated Protein Kinase 14 Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Mitogen Activated Protein Kinase 14 Sales by Country (2027-2032) & (K Units) Table 63. Global Mitogen Activated Protein Kinase 14 Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Mitogen Activated Protein Kinase 14 Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Mitogen Activated Protein Kinase 14 Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Region (2021-2026) Table 67. Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Region (2027-2032) Table 68. Eli Lilly and Company Company Information Table 69. Eli Lilly and Company Business Overview Table 70. Eli Lilly and Company Mitogen Activated Protein Kinase 14 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Eli Lilly and Company Mitogen Activated Protein Kinase 14 Product Portfolio Table 72. Eli Lilly and Company Recent Development Table 73. GlaxoSmithKline Plc Company Information Table 74. GlaxoSmithKline Plc Business Overview Table 75. GlaxoSmithKline Plc Mitogen Activated Protein Kinase 14 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. GlaxoSmithKline Plc Mitogen Activated Protein Kinase 14 Product Portfolio Table 77. GlaxoSmithKline Plc Recent Development Table 78. AstraZeneca Plc Company Information Table 79. AstraZeneca Plc Business Overview Table 80. AstraZeneca Plc Mitogen Activated Protein Kinase 14 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. AstraZeneca Plc Mitogen Activated Protein Kinase 14 Product Portfolio Table 82. AstraZeneca Plc Recent Development Table 83. Zocere, Inc. Company Information Table 84. Zocere, Inc. Business Overview Table 85. Zocere, Inc. Mitogen Activated Protein Kinase 14 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Zocere, Inc. Mitogen Activated Protein Kinase 14 Product Portfolio Table 87. Zocere, Inc. Recent Development Table 88. Toray Industries Company Information Table 89. Toray Industries Business Overview Table 90. Toray Industries Mitogen Activated Protein Kinase 14 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Toray Industries Mitogen Activated Protein Kinase 14 Product Portfolio Table 92. Toray Industries Recent Development Table 93. Synovo GmbH Company Information Table 94. Synovo GmbH Business Overview Table 95. Synovo GmbH Mitogen Activated Protein Kinase 14 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Synovo GmbH Mitogen Activated Protein Kinase 14 Product Portfolio Table 97. Synovo GmbH Recent Development Table 98. Chroma Therapeutics Limited Company Information Table 99. Chroma Therapeutics Limited Business Overview Table 100. Chroma Therapeutics Limited Mitogen Activated Protein Kinase 14 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Chroma Therapeutics Limited Mitogen Activated Protein Kinase 14 Product Portfolio Table 102. Chroma Therapeutics Limited Recent Development Table 103. Chiesi Farmaceutici SpA Company Information Table 104. Chiesi Farmaceutici SpA Business Overview Table 105. Chiesi Farmaceutici SpA Mitogen Activated Protein Kinase 14 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Chiesi Farmaceutici SpA Mitogen Activated Protein Kinase 14 Product Portfolio Table 107. Chiesi Farmaceutici SpA Recent Development Table 108. Astellas Pharma Inc. Company Information Table 109. Astellas Pharma Inc. Business Overview Table 110. Astellas Pharma Inc. Mitogen Activated Protein Kinase 14 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Astellas Pharma Inc. Mitogen Activated Protein Kinase 14 Product Portfolio Table 112. Astellas Pharma Inc. Recent Development Table 113. Array BioPharma Inc. Company Information Table 114. Array BioPharma Inc. Business Overview Table 115. Array BioPharma Inc. Mitogen Activated Protein Kinase 14 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Array BioPharma Inc. Mitogen Activated Protein Kinase 14 Product Portfolio Table 117. Array BioPharma Inc. Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Mitogen Activated Protein Kinase 14 Distributors List Table 121. Mitogen Activated Protein Kinase 14 Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Mitogen Activated Protein Kinase 14 Product Image Figure 2. Global Mitogen Activated Protein Kinase 14 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mitogen Activated Protein Kinase 14 Market Size (2021-2032) & (US$ Million) Figure 4. Global Mitogen Activated Protein Kinase 14 Sales (2021-2032) & (K Units) Figure 5. Global Mitogen Activated Protein Kinase 14 Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Mitogen Activated Protein Kinase 14 Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ralimetinib Mesylate Image Figure 9. Neflamapimod Image Figure 10. Losmapimod Image Figure 11. CHF-6297 Image Figure 12. Others Image Figure 13. Global Mitogen Activated Protein Kinase 14 Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Mitogen Activated Protein Kinase 14 Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Mitogen Activated Protein Kinase 14 Sales Market Share by Type (2021-2032) Figure 16. Global Mitogen Activated Protein Kinase 14 Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Mitogen Activated Protein Kinase 14 Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Type (2021-2032) Figure 19. Gastric Cancer Image Figure 20. Epithelial Ovarian Cancer Image Figure 21. Chronic Inflammation Image Figure 22. Ulcerative Colitis Image Figure 23. Others Image Figure 24. Global Mitogen Activated Protein Kinase 14 Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Mitogen Activated Protein Kinase 14 Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Mitogen Activated Protein Kinase 14 Sales Market Share by Application (2021-2032) Figure 27. Global Mitogen Activated Protein Kinase 14 Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Mitogen Activated Protein Kinase 14 Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Application (2021-2032) Figure 30. North America Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Mitogen Activated Protein Kinase 14 Sales Market Share by Country (2021-2032) Figure 32. U.S. Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Mitogen Activated Protein Kinase 14 Sales Market Share by Country (2021-2032) Figure 37. Germany Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Mitogen Activated Protein Kinase 14 Sales Market Share by Country (2021-2032) Figure 44. China Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Mitogen Activated Protein Kinase 14 Sales Market Share by Country (2021-2032) Figure 52. Brazil Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Mitogen Activated Protein Kinase 14 Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Mitogen Activated Protein Kinase 14 Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Mitogen Activated Protein Kinase 14 Revenue (2021-2032) & (US$ Million) Figure 63. North America Mitogen Activated Protein Kinase 14 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Mitogen Activated Protein Kinase 14 Revenue (2021-2032) & (US$ Million) Figure 65. Europe Mitogen Activated Protein Kinase 14 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Mitogen Activated Protein Kinase 14 Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Mitogen Activated Protein Kinase 14 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Mitogen Activated Protein Kinase 14 Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Mitogen Activated Protein Kinase 14 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Mitogen Activated Protein Kinase 14 Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Mitogen Activated Protein Kinase 14 Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Ralimetinib Mesylate
  • Neflamapimod
  • Losmapimod
  • CHF-6297
  • Others
Applications
  • Gastric Cancer
  • Epithelial Ovarian Cancer
  • Chronic Inflammation
  • Ulcerative Colitis
  • Others
Companies covered
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • AstraZeneca Plc
  • Zocere, Inc.
  • Toray Industries
  • Synovo GmbH
  • Chroma Therapeutics Limited
  • Chiesi Farmaceutici SpA
  • Astellas Pharma Inc.
  • Array BioPharma Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Mitogen Activated Protein Kinase 14 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Mitogen Activated Protein Kinase 14 Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Mitogen Activated Protein Kinase 14 Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Mitogen Activated Protein Kinase 14 Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Mitogen Activated Protein Kinase 14 Market Dynamics
  1. 2.1 Mitogen Activated Protein Kinase 14 Industry Trends
  2. 2.2 Mitogen Activated Protein Kinase 14 Industry Drivers
  3. 2.3 Mitogen Activated Protein Kinase 14 Industry Opportunities and Challenges
  4. 2.4 Mitogen Activated Protein Kinase 14 Industry Restraints
3 Mitogen Activated Protein Kinase 14 Market by Manufacturers
  1. 3.1 Global Mitogen Activated Protein Kinase 14 Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Mitogen Activated Protein Kinase 14 Sales by Manufacturers (2021-2026)
  3. 3.3 Global Mitogen Activated Protein Kinase 14 Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Mitogen Activated Protein Kinase 14 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Mitogen Activated Protein Kinase 14 Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Mitogen Activated Protein Kinase 14 Manufacturers, Product Type & Application
  7. 3.7 Global Mitogen Activated Protein Kinase 14 Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Mitogen Activated Protein Kinase 14 Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Mitogen Activated Protein Kinase 14 Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Mitogen Activated Protein Kinase 14 Tier 1, Tier 2, and Tier 3
4 Mitogen Activated Protein Kinase 14 Market by Type
  1. 4.1 Mitogen Activated Protein Kinase 14 Type Introduction
  2. 4.1.1 Ralimetinib Mesylate
  3. 4.1.2 Neflamapimod
  4. 4.1.3 Losmapimod
  5. 4.1.4 CHF-6297
  6. 4.1.5 Others
  7. 4.2 Global Mitogen Activated Protein Kinase 14 Sales by Type
  8. 4.2.1 Global Mitogen Activated Protein Kinase 14 Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Mitogen Activated Protein Kinase 14 Sales by Type (2021-2032)
  10. 4.2.3 Global Mitogen Activated Protein Kinase 14 Sales Market Share by Type (2021-2032)
  11. 4.3 Global Mitogen Activated Protein Kinase 14 Revenue by Type
  12. 4.3.1 Global Mitogen Activated Protein Kinase 14 Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Mitogen Activated Protein Kinase 14 Revenue by Type (2021-2032)
  14. 4.3.3 Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Type (2021-2032)
5 Mitogen Activated Protein Kinase 14 Market by Application
  1. 5.1 Mitogen Activated Protein Kinase 14 Application Introduction
  2. 5.1.1 Gastric Cancer
  3. 5.1.2 Epithelial Ovarian Cancer
  4. 5.1.3 Chronic Inflammation
  5. 5.1.4 Ulcerative Colitis
  6. 5.1.5 Others
  7. 5.2 Global Mitogen Activated Protein Kinase 14 Sales by Application
  8. 5.2.1 Global Mitogen Activated Protein Kinase 14 Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Mitogen Activated Protein Kinase 14 Sales by Application (2021-2032)
  10. 5.2.3 Global Mitogen Activated Protein Kinase 14 Sales Market Share by Application (2021-2032)
  11. 5.3 Global Mitogen Activated Protein Kinase 14 Revenue by Application
  12. 5.3.1 Global Mitogen Activated Protein Kinase 14 Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Mitogen Activated Protein Kinase 14 Revenue by Application (2021-2032)
  14. 5.3.3 Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Application (2021-2032)
6 Global Mitogen Activated Protein Kinase 14 Sales by Region
  1. 6.1 Global Mitogen Activated Protein Kinase 14 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mitogen Activated Protein Kinase 14 Sales by Region (2021-2032)
  3. 6.2.1 Global Mitogen Activated Protein Kinase 14 Sales by Region (2021-2026)
  4. 6.2.2 Global Mitogen Activated Protein Kinase 14 Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Mitogen Activated Protein Kinase 14 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Mitogen Activated Protein Kinase 14 Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Mitogen Activated Protein Kinase 14 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Mitogen Activated Protein Kinase 14 Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Mitogen Activated Protein Kinase 14 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Mitogen Activated Protein Kinase 14 Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Mitogen Activated Protein Kinase 14 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Mitogen Activated Protein Kinase 14 Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Mitogen Activated Protein Kinase 14 Revenue by Region
  1. 7.1 Global Mitogen Activated Protein Kinase 14 Revenue by Region
  2. 7.1.1 Global Mitogen Activated Protein Kinase 14 Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Mitogen Activated Protein Kinase 14 Revenue by Region (2021-2026)
  4. 7.1.3 Global Mitogen Activated Protein Kinase 14 Revenue by Region (2027-2032)
  5. 7.1.4 Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Mitogen Activated Protein Kinase 14 Revenue (2021-2032)
  8. 7.2.2 North America Mitogen Activated Protein Kinase 14 Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Mitogen Activated Protein Kinase 14 Revenue (2021-2032)
  11. 7.3.2 Europe Mitogen Activated Protein Kinase 14 Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Mitogen Activated Protein Kinase 14 Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Mitogen Activated Protein Kinase 14 Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Mitogen Activated Protein Kinase 14 Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Mitogen Activated Protein Kinase 14 Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly and Company
  2. 8.1.1 Eli Lilly and Company Company Information
  3. 8.1.2 Eli Lilly and Company Business Overview
  4. 8.1.3 Eli Lilly and Company Mitogen Activated Protein Kinase 14 Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly and Company Mitogen Activated Protein Kinase 14 Product Portfolio
  6. 8.1.5 Eli Lilly and Company Recent Developments
  7. 8.2 GlaxoSmithKline Plc
  8. 8.2.1 GlaxoSmithKline Plc Company Information
  9. 8.2.2 GlaxoSmithKline Plc Business Overview
  10. 8.2.3 GlaxoSmithKline Plc Mitogen Activated Protein Kinase 14 Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Plc Mitogen Activated Protein Kinase 14 Product Portfolio
  12. 8.2.5 GlaxoSmithKline Plc Recent Developments
  13. 8.3 AstraZeneca Plc
  14. 8.3.1 AstraZeneca Plc Company Information
  15. 8.3.2 AstraZeneca Plc Business Overview
  16. 8.3.3 AstraZeneca Plc Mitogen Activated Protein Kinase 14 Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Plc Mitogen Activated Protein Kinase 14 Product Portfolio
  18. 8.3.5 AstraZeneca Plc Recent Developments
  19. 8.4 Zocere, Inc.
  20. 8.4.1 Zocere, Inc. Company Information
  21. 8.4.2 Zocere, Inc. Business Overview
  22. 8.4.3 Zocere, Inc. Mitogen Activated Protein Kinase 14 Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Zocere, Inc. Mitogen Activated Protein Kinase 14 Product Portfolio
  24. 8.4.5 Zocere, Inc. Recent Developments
  25. 8.5 Toray Industries
  26. 8.5.1 Toray Industries Company Information
  27. 8.5.2 Toray Industries Business Overview
  28. 8.5.3 Toray Industries Mitogen Activated Protein Kinase 14 Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Toray Industries Mitogen Activated Protein Kinase 14 Product Portfolio
  30. 8.5.5 Toray Industries Recent Developments
  31. 8.6 Synovo GmbH
  32. 8.6.1 Synovo GmbH Company Information
  33. 8.6.2 Synovo GmbH Business Overview
  34. 8.6.3 Synovo GmbH Mitogen Activated Protein Kinase 14 Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Synovo GmbH Mitogen Activated Protein Kinase 14 Product Portfolio
  36. 8.6.5 Synovo GmbH Recent Developments
  37. 8.7 Chroma Therapeutics Limited
  38. 8.7.1 Chroma Therapeutics Limited Company Information
  39. 8.7.2 Chroma Therapeutics Limited Business Overview
  40. 8.7.3 Chroma Therapeutics Limited Mitogen Activated Protein Kinase 14 Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Chroma Therapeutics Limited Mitogen Activated Protein Kinase 14 Product Portfolio
  42. 8.7.5 Chroma Therapeutics Limited Recent Developments
  43. 8.8 Chiesi Farmaceutici SpA
  44. 8.8.1 Chiesi Farmaceutici SpA Company Information
  45. 8.8.2 Chiesi Farmaceutici SpA Business Overview
  46. 8.8.3 Chiesi Farmaceutici SpA Mitogen Activated Protein Kinase 14 Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Chiesi Farmaceutici SpA Mitogen Activated Protein Kinase 14 Product Portfolio
  48. 8.8.5 Chiesi Farmaceutici SpA Recent Developments
  49. 8.9 Astellas Pharma Inc.
  50. 8.9.1 Astellas Pharma Inc. Company Information
  51. 8.9.2 Astellas Pharma Inc. Business Overview
  52. 8.9.3 Astellas Pharma Inc. Mitogen Activated Protein Kinase 14 Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Astellas Pharma Inc. Mitogen Activated Protein Kinase 14 Product Portfolio
  54. 8.9.5 Astellas Pharma Inc. Recent Developments
  55. 8.10 Array BioPharma Inc.
  56. 8.10.1 Array BioPharma Inc. Company Information
  57. 8.10.2 Array BioPharma Inc. Business Overview
  58. 8.10.3 Array BioPharma Inc. Mitogen Activated Protein Kinase 14 Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Array BioPharma Inc. Mitogen Activated Protein Kinase 14 Product Portfolio
  60. 8.10.5 Array BioPharma Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Mitogen Activated Protein Kinase 14 Value Chain Analysis
  2. 9.1.1 Mitogen Activated Protein Kinase 14 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Mitogen Activated Protein Kinase 14 Production Mode & Process
  6. 9.2 Mitogen Activated Protein Kinase 14 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Mitogen Activated Protein Kinase 14 Distributors
  9. 9.2.3 Mitogen Activated Protein Kinase 14 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst